IRF7 sirna

IRF7 siRNA (Human)

Cat. Num. AAA8229782

• Gene Names: IRF7; IMD39; IRF7A; IRF7B; IRF7C; IRF7H; IRF-7H
• Reactivity: Human
• Applications: RNA Interference (RNAi)
• Purity: > 97%
• Synonyms: IRF7; IRF7 siRNA (Human); Interferon regulatory factor 7; IRF-7; IRF7 sirna

• Host: Synthetic
• Reactivity: Human
• Specificity: IRF7 siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
• Purity/Purification: > 97%
• Form/Format: Lyophilized powder
• Sequence Length: 503

• Applicable Applications for IRF7 sirna: RNA Interference (RNAi)
• Quality Control: Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
• Directions for Use: We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
• Components: We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human IRF7 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
• Preparation and Storage: Shipped at 4 degree C. Store at -20 degree C for one year.

Related Product Information for IRF7 sirna

siRNA to inhibit IRF7 expression using RNA interference

NCBI and Uniprot Product Information

• NCBI GI #: 4758610
• NCBI GeneID: 3665
• NCBI Accession #: NP_001563.2
• NCBI GenBank Nucleotide #: NM_001572.3
• UniProt Accession #: Q92985; O00331; O00332; O00333; O75924; Q9UE79; B9EGL3
• Molecular Weight: 55,635 Da
• NCBI Official Full Name: interferon regulatory factor 7 isoform a
• NCBI Official Synonym Full Names: interferon regulatory factor 7
• NCBI Official Symbol: IRF7
• NCBI Official Synonym Symbols: IMD39; IRF7A; IRF7B; IRF7C; IRF7H; IRF-7H
• NCBI Protein Information: interferon regulatory factor 7
• UniProt Protein Name: Interferon regulatory factor 7
• Protein Family: Interferon regulatory factor
• UniProt Gene Name: IRF7
• UniProt Synonym Gene Names: IRF-7
• UniProt Entry Name: IRF7_HUMAN

NCBI Description

IRF7 encodes interferon regulatory factor 7, a member of the interferon regulatory transcription factor (IRF) family. IRF7 has been shown to play a role in the transcriptional activation of virus-inducible cellular genes, including interferon beta chain genes. Inducible expression of IRF7 is largely restricted to lymphoid tissue. Multiple IRF7 transcript variants have been identified, although the functional consequences of these have not yet been established. [provided by RefSeq, Jul 2008]

Uniprot Description

IRF7: Key transcriptional regulator of type I interferon (IFN)-dependent immune responses and plays a critical role in the innate immune response against DNA and RNA viruses. Regulates the transcription of type I IFN genes (IFN-alpha and IFN-beta) and IFN-stimulated genes (ISG) by binding to an interferon-stimulated response element (ISRE) in their promoters. Can efficiently activate both the IFN-beta (IFNB) and the IFN-alpha (IFNA) genes and mediate their induction via both the virus-activated, MyD88- independent pathway and the TLR-activated, MyD88-dependent pathway. Required during both the early and late phases of the IFN gene induction but is more critical for the late than for the early phase. Exists in an inactive form in the cytoplasm of uninfected cells and following viral infection, double-stranded RNA (dsRNA), or toll-like receptor (TLR) signaling, becomes phosphorylated by IKBKE and TBK1 kinases. This induces a conformational change, leading to its dimerization and nuclear localization where along with other coactivators it can activate transcription of the type I IFN and ISG genes. Can also play a role in regulating adaptive immune responses by inducing PSMB9/LMP2 expression, either directly or through induction of IRF1. Binds to the Q promoter (Qp) of EBV nuclear antigen 1 a (EBNA1) and may play a role in the regulation of EBV latency. Can activate distinct gene expression programs in macrophages and regulate the anti-tumor properties of primary macrophages. Monomer. Homodimer; phosphorylation-induced. Heterodimer with IRF3. Interacts with TICAM1 and TICAM2. Interacts with rotavirus A NSP1; this interaction leads to the proteasome- dependent degradation of IRF7. Interacts with Epstein-Barr virus LF2. Interacts with MYD88 AND TRAF6. By type I interferon (IFN) and viruses. Expressed predominantly in spleen, thymus and peripheral blood leukocytes. In the absence of viral infection, maintained as a monomer in an autoinhibited state and phosphorylation disrupts this autoinhibition leading to the liberation of the DNA- binding and dimerization activities and its nuclear localization where it can activate type I IFN and ISG genes. Belongs to the IRF family. 4 isoforms of the human protein are produced by alternative splicing.

Protein type: Transcription factor; DNA-binding

Chromosomal Location of Human Ortholog: 11p15.5

Cellular Component: nucleoplasm; cytoplasm; endosome membrane; nucleus; cytosol

Molecular Function: protein binding; DNA binding

Biological Process: transcription from RNA polymerase II promoter; positive regulation of transcription, DNA-dependent; establishment of viral latency; toll-like receptor 3 signaling pathway; negative regulation of transcription from RNA polymerase II promoter; regulation of adaptive immune response; regulation of MyD88-independent toll-like receptor signaling pathway; positive regulation of interferon-beta production; positive regulation of interferon type I production; interferon type I biosynthetic process; toll-like receptor 4 signaling pathway; positive regulation of interferon-alpha production; regulation of interferon type I production; regulation of immune response; cytokine and chemokine mediated signaling pathway; response to virus; MyD88-independent toll-like receptor signaling pathway; interferon-alpha production; regulation of MyD88-dependent toll-like receptor signaling pathway; regulation of monocyte differentiation; toll-like receptor signaling pathway; innate immune response; positive regulation of transcription from RNA polymerase II promoter; immunoglobulin mediated immune response; toll-like receptor 9 signaling pathway; response to DNA damage stimulus; interferon-beta production

Disease: Immunodeficiency 39